PerkinElmer and George Mason University Announce Alliance to Develop Novel Proteomic Technologies
Biomarker Identification for Early Cancer Detection
The alliance initially calls for the creation of a new proteomics technology to accurately measure and detect specific protein fragments found in human blood, which are potential biomarkers for disease. The alliance builds on a recent discovery by George Mason University researchers, Drs. Emanuel F. Petricoin and Lance A. Liotta, of an archive of protein fragments in human blood.
"This untapped archive of protein fragments from diverse tissue and cellular origins may offer vital disease-related information," theorized Liotta. "High-abundance proteins, such as albumin, found in blood serum appear to act as molecular magnets that mop up the fragments, and our work to date demonstrates that these fragments can be identified, measured and analyzed in the context of specific diseases, such as early stage ovarian cancer."
Petricoin explained that the alliance goes beyond the rigorous validation and discovery of new markers for cancer to a new and unprecedented paradigm for disease detection using a new type of biomarker. "The new concept - that disease detection lies in the information stored in fragments of proteins - requires both the precise mass and the amino acid sequence of the candidate biomarker," he said.
Topics
Organizations
Other news from the department science
These products might interest you
Kjel- / Dist Line by Büchi
Kjel- and Dist Line - steam distillation and Kjeldahl applications
Maximum accuracy and performance for your steam distillation and Kjeldahl applications
AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.